Treatment-related toxicities from conventional chemotherapy can cause suffering in many patients with childhood leukemia. The search continues for medications that are effective while producing fewer adverse effects. Pediatric hematologist/oncologist, Seth Corey, MD, MPH, explains his latest study repurposing the antimalarial drug, mefloquine.
Evidence regarding the genetic pathways involved in Scwachman-Diamond syndrome and severe congenital neutropenia is emerging. Clinician researcher Seth Corey, MD, MPH, explains his work to identify patients at highest risk and intervene before acute myeloid leukemia develops.
Azacitidine could help patients with acute myelogenous leukemia or myelodysplastic syndrome who relapse after transplant achieve remission.
Although studies have established the prognostic significance of specific genetic mutations in AML and MDS, the role of mutations as prognostic factors of outcomes after HCT is still unclear.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Abandoning apoptosis in favor of selective differentiation has proven a fruitful strategy in the search for AML treatments.
A maternal-fetal medicine expert answers six vital questions about balancing cancer and pregnancy care, revealing the benefits of a team-based approach.
A new study shows that physicians may be overtreating patients with well-differentiated thyroid cancer and putting them at risk for more deadly diseases.
Early trial data show that precision therapy enasidenib can induce durable complete remission in patients with relapsed/refractory acute myeloid leukemia.
Several promising antibody-based treatment strategies are in development for acute lymphoblastic leukemia and acute myeloid leukemia. These could change the decade-old treatment paradigm.